Which has preferable valuation & earnings, PHVS or RGNX?

REGENXBIO has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A REGENXBIO $170.44M 2.77 -$193.88M -$3.79 N/A

Is PHVS or RGNX more profitable?

Pharvaris has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Pharvaris' return on equity of -61.40% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% REGENXBIO -112.58% -220.07% -46.04%

Does the media refer more to PHVS or RGNX?

In the previous week, Pharvaris had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.98 beat Pharvaris' score of 0.31 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LKFT or RGNX?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 3 articles in the media. REGENXBIO's average media sentiment score of 0.98 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.89 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, RGNX or NVAX?

Novavax has higher revenue and earnings than REGENXBIO. Novavax is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.77 -$193.88M -$3.79 N/A Novavax $413.80M 5.11 $440.30M -$1.52 N/A

Is RGNX or NVAX more profitable?

Novavax has a net margin of -59.87% compared to REGENXBIO's net margin of -112.58%. Novavax's return on equity of -14.82% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Novavax -59.87% -14.82% -13.35%

Does the media favor RGNX or NVAX?

In the previous week, Novavax had 7 more articles in the media than REGENXBIO. MarketBeat recorded 10 mentions for Novavax and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.98 beat Novavax's score of 0.20 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher earnings & valuation, RGNX or BHVN?

REGENXBIO has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.77 -$193.88M -$3.79 N/A Biohaven N/A N/A -$738.82M -$4.64 N/A

Is RGNX or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Biohaven N/A -1,328.94% -138.27%

Does the media refer more to RGNX or BHVN?

In the previous week, REGENXBIO had 1 more articles in the media than Biohaven. MarketBeat recorded 3 mentions for REGENXBIO and 2 mentions for Biohaven. REGENXBIO's average media sentiment score of 0.98 beat Biohaven's score of 0.33 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, VIR or RGNX?

REGENXBIO has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vir Biotechnology $68.56M 25.84 -$437.99M -$1.86 N/A REGENXBIO $170.44M 2.77 -$193.88M -$3.79 N/A

Does the media favor VIR or RGNX?

In the previous week, Vir Biotechnology had 18 more articles in the media than REGENXBIO. MarketBeat recorded 21 mentions for Vir Biotechnology and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.98 beat Vir Biotechnology's score of 0.17 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

REGENXBIO (RGNX) Competitors

$7.08 -0.09 (-1.19%)

As of 11:13 AM Eastern

Compare

RGNX vs. PHVS, LKFT, NVAX, BHVN, and VIR

Should you buy REGENXBIO stock or one of its competitors? REGENXBIO's main competitors and comparable companies include Pharvaris (PHVS), Lakefront Biotherapeutics American Depositary Shares (LKFT), Novavax (NVAX), Biohaven (BHVN), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does REGENXBIO compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Pharvaris has a beta of -2.46, suggesting that its share price is 346% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Pharvaris has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Pharvaris' return on equity of -61.40% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
REGENXBIO	-112.58%	-220.07%	-46.04%

REGENXBIO has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
REGENXBIO	$170.44M	2.77	-$193.88M	-$3.79	N/A

Pharvaris presently has a consensus target price of $58.60, suggesting a potential upside of 97.71%. REGENXBIO has a consensus target price of $23.17, suggesting a potential upside of 223.56%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

88.1% of REGENXBIO shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Pharvaris had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.98 beat Pharvaris' score of 0.31 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

REGENXBIO beats Pharvaris on 10 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
REGENXBIO	-112.58%	-220.07%	-46.04%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 3 articles in the media. REGENXBIO's average media sentiment score of 0.98 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.89 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than REGENXBIO. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.57	$363.05M	-$1.41	N/A
REGENXBIO	$170.44M	2.77	-$193.88M	-$3.79	N/A

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $37.00, indicating a potential upside of 23.62%. REGENXBIO has a consensus target price of $23.17, indicating a potential upside of 223.56%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

REGENXBIO beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 14 factors compared between the two stocks.

How does REGENXBIO compare to Novavax?

REGENXBIO (NASDAQ:RGNX) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Novavax had 7 more articles in the media than REGENXBIO. MarketBeat recorded 10 mentions for Novavax and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.98 beat Novavax's score of 0.20 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

REGENXBIO has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Novavax has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market.

Novavax has a net margin of -59.87% compared to REGENXBIO's net margin of -112.58%. Novavax's return on equity of -14.82% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Novavax	-59.87%	-14.82%	-13.35%

Novavax has higher revenue and earnings than REGENXBIO. Novavax is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.77	-$193.88M	-$3.79	N/A
Novavax	$413.80M	5.11	$440.30M	-$1.52	N/A

REGENXBIO currently has a consensus price target of $23.17, suggesting a potential upside of 223.56%. Novavax has a consensus price target of $13.14, suggesting a potential upside of 2.52%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Novavax beats REGENXBIO on 9 of the 17 factors compared between the two stocks.

How does REGENXBIO compare to Biohaven?

REGENXBIO (NASDAQ:RGNX) and Biohaven (NYSE:BHVN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

REGENXBIO currently has a consensus price target of $23.17, suggesting a potential upside of 223.56%. Biohaven has a consensus price target of $18.69, suggesting a potential upside of 63.34%. Given REGENXBIO's stronger consensus rating and higher possible upside, equities research analysts clearly believe REGENXBIO is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

REGENXBIO has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.77	-$193.88M	-$3.79	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Biohaven has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Biohaven	N/A	-1,328.94%	-138.27%

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

REGENXBIO has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, REGENXBIO had 1 more articles in the media than Biohaven. MarketBeat recorded 3 mentions for REGENXBIO and 2 mentions for Biohaven. REGENXBIO's average media sentiment score of 0.98 beat Biohaven's score of 0.33 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

REGENXBIO beats Biohaven on 12 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Vir Biotechnology has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

In the previous week, Vir Biotechnology had 18 more articles in the media than REGENXBIO. MarketBeat recorded 21 mentions for Vir Biotechnology and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.98 beat Vir Biotechnology's score of 0.17 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology currently has a consensus target price of $21.86, indicating a potential upside of 108.76%. REGENXBIO has a consensus target price of $23.17, indicating a potential upside of 223.56%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vir Biotechnology has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Vir Biotechnology's return on equity of -29.99% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
REGENXBIO	-112.58%	-220.07%	-46.04%

REGENXBIO has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	25.84	-$437.99M	-$1.86	N/A
REGENXBIO	$170.44M	2.77	-$193.88M	-$3.79	N/A

Summary

REGENXBIO beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$467.22M	$3.92B	$7.43B	$12.84B
Dividend Yield	N/A	3.66%	2.51%	19.61%
P/E Ratio	-1.87	12.63	274.90	25.18
Price / Sales	2.74	1,214.82	626.16	99.71
Price / Cash	N/A	118.95	76.19	51.56
Price / Book	3.49	16.09	10.38	5.95
Net Income	-$193.88M	-$22.69M	$3.50B	$380.92M
7 Day Performance	-12.33%	-6.56%	-3.95%	-3.44%
1 Month Performance	-11.34%	-11.92%	-7.17%	-5.48%
1 Year Performance	-42.67%	2.98%	1.66%	-4.64%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	2.9873 of 5 stars	$7.08 -1.2%	$23.17 +227.4%	-41.8%	$467.22M	$170.44M	N/A	371
PHVS Pharvaris	3.1096 of 5 stars	$30.87 -1.0%	$59.87 +93.9%	+36.1%	$2.02B	N/A	N/A	148	Analyst Forecast
LKFT Lakefront Biotherapeutics American Depositary Shares	2.918 of 5 stars	$29.82 +1.5%	$37.00 +24.1%	-12.1%	$1.97B	$1.26B	N/A	1,310
NVAX Novavax	1.4799 of 5 stars	$11.92 +14.0%	$14.00 +17.4%	+43.9%	$1.96B	$1.12B	N/A	749	Analyst Forecast
BHVN Biohaven	3.2418 of 5 stars	$12.98 +0.8%	$18.69 +44.0%	-34.3%	$1.96B	N/A	N/A	274

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors